Vivostat® Co-Delivery

slow release of substance

Vivostat® Co-Delivery

The revolutionary Vivostat® Co-Delivery system makes it possible to co-apply a desired substance1 with the Vivostat® sealant and matrix solutions.

The opportunities with the Vivostat® Co-Delivery system are vast and the system allows the surgeon to apply a selected substance easily and effectively. Furthermore, it may be possible to reduce the total cost of a procedure by using the Vivostat® Co-Delivery system2.

Options for co-delivery include:


  • Antimicrobials
  • Chemotherapeutics
  • Pain medications


  • Stem cells
  • Skin cells

Products characteristics

None of the Vivostat® sealant/matrix solutions has thrombin added (unlike most other sealants and PRP products). This is highly beneficial to the Vivostat® Co-Delivery system as thrombin activation has been shown to have a negative effect on cell survival3. The fibrin membrane found in all Vivostat® products has, furthermore, been shown to postpone the degradation process of the substance. This means that the fibrin membrane ensures a slow and sustained release of the substance offering a prolonged effect4. The slow release of active antibiotics in combination with a Vivostat® solution has also been documented in an in-vitro study5.

Benefits Vivostat® Co-Delivery

Co-applying drugs, cells etc. with a Vivostat® sealant or matrix solution offers the surgeon and the patient a number of benefits:

how does the co-delivery system work?

When you co-deliver, you can apply up to 5 ml of substance with the sealant/matrix solution.

The substance is applied using the Vivostat® Spraypen or endoscopic solution which enables the surgeon to apply the substance accurately and intermittently throughout the entire procedure.

The substance and the sealant or matrix solution is mixed once it leaves the tip of the application device and polymerizes immediately upon application – this way the substances stay where they are intended to act.

FAQ - Vivostat® Co-delivery

We have gathered the most frequently asked questions about Vivostat® Co-Delivery.

If you have any other questions, you are always welcome to contact your local distributor or Vivostat.

It is possible to apply a maximum of 5.3 mL of substance depending on the concentration of fibrin and volume of the sealant or matrix solution harvested. Learn more about how to calculate and how to apply in the Vivostat® Co-Delivery guide.
In order to apply a powder substance you need to dissolve the powder in a liquid medium and adjust the pH level.
The Vivostat® Spraypen – Co-Delivery requires 4 channels in the tube (air, pH10, sealant/matrix and substance). Since 1 of these channels in a normal Vivostat® Spraypen is used by the pen button to activate application it is not possible to have a pen button. That is why it is necessary to use the Foot Switch for activation.
Yes, it is possible to co-apply sealant or matrices with the Vivostat® Endoscopic Kit – Co-Delivery.
The co-delivered substance must be acidic or neutral (pH7).

The substance volume may be too high or the pH level may be above 7.

We have in some circumstances experienced no polymerization with:

  • Cefepim
  • Clindamycin/Dalacin
  • Cubicin
  • Ertapenem6


We have great experience with good polymerization using:

  • Amikacin6
  • Augmentin
  • Bacitracin (Baneocin)
  • Biklin
  • Cefrom
  • Ciprofloxacin
  • Ciprofloxacin + Colistin
  • Colistin (Promixin)
  • Flucloxacillin
  • Gentamycon
  • Penem – certain kinds 
  • Tazobactam (Piperacillin/Tazonam)
  • Teicoplanin6
  • Tobramycin (Nebcina)
  • Tobramycin + Colistin
  • Unasyn (Ampicillin/Sulbactam6)
  • Vancomycon

The list might not be complete.

PRODUCT order codes vivostat® Co-Delivery

Application devices

The Vivostat® System offers a variety of different disposable application devic­es as well as a number of reusable handles.

Vivostat® System

Using the Vivostat® System, you can prepare autologous platelets enriched fibrin with multiple growth factors embedded in a matrix. 

  1. The amount of substance and its effect on the patient is always the responsibility of the surgeon.
  2. Vadalà, G., Di Martino, A., Tirindelli, M. C., Denaro, L., & Denaro, V. (2008), Use of autologous bone marrow cells concentrate enriched with platelet-rich fibrin on corticocancellous bone allograft for posterolateral multilevel cervical fusion, Journal of tissue engineering and regenerative medicine, 2(8), 515–520, 
  3. Gugerell, A., Schossleitner, K., Wolbank, S., Nürnberger, S., Redl, H., Gulle, H., Goppelt, A., Bittner, M., & Pasteiner, W. (2012). High thrombin concentrations in fibrin sealants induce apoptosis in human keratinocytes. Journal of Biomedical Materials Research Part A, 100A(5), 1239–1247.
  4. Lardinois, D., Jung, F., Opitz, I., Rentsch, K., Latkoczy, C., Vuong, V., Varga, Z., Rousson, V., Günther, D., Bodis, S., Stahel, R. A., & Weder, W. (2006b). Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. The Journal of Thoracic and Cardiovascular Surgery, 131(3), 697-703.e3.
  5. Knafl, D., Thalhammer, F., & Vossen, M. G.  (2017), In-vitro release pharmacokinetics of amikacin teicoplanin and polyhexanide in a platelet rich fibrin layer (PRF) a laboratory evaluation of a modern, autologous wound treatment, PLoS One e, 12(7), e0181090,
  6. Vivostat® Co-Delivery: Antibiotics experienced use (2024, March 11). Medical University of Vienna